ABCA7 and early-onset autosomal dominant Alzheimer disease: However, based on the Accelerating Medicines Partnership—Alzheimer’s Disease (AMP-AD) consortium which includes the currently largest collaborative post-mortem brain RNA-sequencing project, no significant differential expression of ABCA7 is observed between patients and controls [https://agora.ampadportal.org; accessed January 2019].